Lantern Pharma Establishes AI Center of Excellence in India to Scale Drug Discovery Platform

Lantern Pharma (NASDAQ: LTRN) announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India, marking a strategic inflection point as the company moves to industrialize its AI-enabled drug discovery capabilities at global scale. The Bengaluru hub will serve as Lantern's global scale-up center for its proprietary RADR AI platform, expanding computational capacity, technical talent, and continuous development cycles to support both its internal oncology pipeline and a growing roster of pharmaceutical and academic collaborators.

The initiative will accelerate development of Lantern's specialized large language and quantitative models for molecular assessment, optimization, and de novo drug generation, while enabling phased expansion beyond oncology into additional disease areas. This expansion occurs while maintaining a cash-neutral financial impact during early deployment, representing a significant operational achievement for the clinical-stage biotechnology company. The company's proprietary RADR AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials, capabilities that will be enhanced through the new Indian operations.

Lantern's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations. The establishment of the Bengaluru center represents a critical step in scaling the company's technology infrastructure to support both current and future drug development programs. By leveraging India's technical talent pool and establishing continuous development cycles, Lantern aims to significantly accelerate its drug discovery timelines while maintaining financial discipline. The move positions the company to better serve its growing roster of pharmaceutical and academic collaborators who seek to leverage AI-driven approaches to oncology research.

The strategic importance of this expansion lies in its potential to transform how AI is applied to drug discovery at industrial scale. Rather than treating AI as a supplementary tool, Lantern is building infrastructure to make AI the central engine of its discovery operations. This approach could potentially reduce the time and cost associated with bringing new cancer therapies to market while improving precision targeting of patient populations. The cash-neutral nature of the early deployment phase demonstrates careful financial planning while pursuing aggressive technological expansion. For investors and industry observers, this move signals Lantern's transition from a company developing AI tools to one building an AI-powered drug discovery ecosystem with global reach and scalable infrastructure.

The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. The full press release announcing this strategic expansion can be viewed at https://ibn.fm/pKL9o. This development comes as the biotechnology sector increasingly recognizes the transformative potential of artificial intelligence in accelerating drug discovery and development timelines while improving precision medicine approaches.